INNOVATE (VATE) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 consolidated revenue was $242.2 million, down 35.5% year-over-year, mainly due to lower Infrastructure segment revenue, while Life Sciences and Spectrum segments posted strong growth.
Net loss attributable to shareholders was $15.3 million ($1.18 per diluted share), compared to $7.3 million loss in Q3 2023, reflecting a reverse stock split.
Adjusted EBITDA was $16.8 million, down from $22.1 million in the prior year period.
Substantial doubt exists about the company's ability to continue as a going concern due to upcoming debt maturities and cross-default provisions; management is exploring refinancing, asset sales, and capital raising.
DBM Global achieved $6.2 million net income and $20.9 million Adjusted EBITDA, with margin improvement year-over-year.
Financial highlights
Infrastructure revenue fell 37% to $232.8 million, driven by project timing and completion of large commercial projects.
Life Sciences revenue rose 400% to $3 million, led by R2's Glacial FX system sales.
Spectrum revenue increased to $6.4 million, up $1 million year-over-year, with Adjusted EBITDA improving to $1.7 million from a $300,000 loss.
Company cash and equivalents were $51 million at quarter end, down from $80.8 million at year-end 2023.
Total principal outstanding indebtedness was $699.2 million, down $23.6 million from year-end 2023.
Outlook and guidance
Full-year results expected to be slightly lower than last year, with a lighter second half as previously signaled.
DBM's backlog remains robust at $1.1 billion, positioning the business well for 2025.
Management highlights substantial doubt about the company's ability to continue as a going concern due to upcoming debt maturities and cross-default provisions.
Spectrum segment anticipates further OTA network opportunities and is exploring ATSC 3.0 and 5G broadcast TV.
R2 Technologies expects continued growth in system sales and utilization.
Latest events from INNOVATE
- Major asset sales will eliminate most revenue, with proceeds used for debt repayment, not shareholders.VATE
Registration filing - Q2 2026 revenue jumped 74.2% to $421.6M, with net income of $10.4M and major asset sales underway.VATE
Q2 2026 - All proposals passed, directors elected, and no questions raised during the Q&A session.VATE
AGM 2026 - Revenue up 33% to $364.8M, net loss narrowed, but debt maturities pose going concern risk.VATE
Q1 2026 - Annual meeting to vote on directors, compensation, equity plan, and auditor ratification.VATE
Proxy filing - Board recommends FOR all proposals, with focus on growth, governance, and executive alignment.VATE
Proxy filing - Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 2025 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 2024 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 2024